Apart from identifying potentially novel differentially methylated CpG sites in individuals with incident type 2 diabetes versus those without, we explored how many of the previously identified type 2 diabetes-associated CpG sites were replicated, particularly in Black adults since previous DNAm studies of incident type 2 diabetes did not consider individuals of African descent. We compiled a list of EWAS of both incident and prevalent type 2 diabetes from the NCBI PubMed database by searching the terms “DNA methylation”, “type 2 diabetes” and “epigenome-wide association analysis” or “EWAS” as of July 21, 2023. We included EWAS that used DNAm data measured through the Illumina platform (HM450K array or other variation of the Illumina Methylation array such as 27K, EPIC) as either exposure or outcome based on study design. We shortlisted a total of 17 studies including studies on DNAm from various tissues such as pancreatic islets, liver biopsy, subcutaneous and visceral adipose tissues, and whole blood (Supplementary Table 1).18 (link)–26 (link), 47 (link)–54 Study-specific significance thresholds were used to obtain candidate CpG sites from each study. A total of 18,131 candidate CpG sites (unique candidate CpG sites: 419 from blood, 15,728 from adipose, 287 from liver, and 1,924 from pancreas) were looked up in the results from our primary time-to-event analysis.